

Special Issue

Cellular and Molecular Biology of Neurodegenerative Disorders, 2nd Edition

Message from the Guest Editor

I am pleased to share that I am working as a on a Special Issue entitled “Cellular and Molecular Biology of Neurodegenerative Disorders, 2nd Edition” in the open access journal *Biomedicines*. In this Special Issue, we aim to publish original research articles and reviews in which neurodegenerative diseases are studied at the level of their underlying mechanisms. A major challenge in neurodegeneration research is finding strategies that can contribute to achieving early diagnosis, patients’ classification and stratification, and the development of disease-modifying therapeutic approaches. With this in mind, one main objective of the Special Issue is to unveil the complex network of cellular and molecular mechanisms that trigger disease onset and progression. Omics techniques, being unbiased and global, represent the most promising strategy to overcome this complexity, and achieve this by using bioinformatic tools for omics data integration within a “systems biology” perspective.

Guest Editor

Dr. Marta Lualdi

Department of Science and High Technology, University of Insubria,
22100 Como, Italy

Deadline for manuscript submissions

30 November 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/274391

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).